Moderna expects COVID vaccine data in young children in March - Bloomberg
Evgenia Parajanian/iStock Editorial via Getty Images


Moderna (MRNA
-0.1%) said that it plans to report data on its COVID-19 vaccine in children between the ages of 2 and 5 years old in March, Bloomberg reports.
"If the data is supportive and subject to regulatory consultation, Moderna may proceed with regulatory filings for children 2-5 years of age thereafter," the company said.

Moderna is awaiting an FDA decision on amending its Emergency Use Authorization for its vaccine to include 12 to 17-year-olds.

Dear readers: We recognize that politics often intersects with the financial news of the day, so we invite you to click here to join the separate political discussion.